ImmunityBio, Inc. (IBRX) - Stock Analysis
Last updated: Jan 13, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
ImmunityBio is a hot idea driven by accelerating commercial revenue growth (700% annual increase in 2025), regulatory approvals expanding markets, positive clinical data mid-January 2026, nearly doubled stock price in past month, despite ongoing financial risks.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Reduced losses ⢠High leverage ⢠Ongoing cash-burn IBRX has materially reduced losses and grown revenue YTD, but severe long-term debt, negative equity and falling cash keep the balance sheet and valuation under pressure.
Price Behavior
Key Price Behavior Insights: ⢠Steady ascent ⢠Moderate gains ⢠Support holding Support Level: $2.08â$2.14 Resistance Level: $2.59 Over the last month IBRX has shown steady, moderate upward momentum from about $2.08 to $2.59, indicating healthy accumulation with support near $2.08â$2.14 and resistance at $2.59âwatch for a breakout above $2.59 or a failure to hold $2.14.
Sentiment & News
Key News Insights: ⢠High efficacy data ⢠Leadership recognition ⢠Global partnerships ImmunityBio's strong 96% threeâyear survival ANKTIVAÂŽ data, leadership recognition, upcoming regulatory catalysts and new U.S.âSaudi collaboration position the company for potential upside into 2026.
AI Summary
ImmunityBio has shifted from a binary clinical-stage bet to a nascent commercial oncology franchise anchored by ANKTIVA, so investors should now prioritize tracking quarterly ANKTIVA sales growth and cash runway rather than focusing solely on trial readouts. The key inflection is whether commercial momentum plus EU conditional CMA and durable reimbursement can stabilize cash and avoid dilutive refinancingâsustained revenue growth de-risks the story, slippage will likely force dilution.
Description
ImmunityBio, Inc. is a clinical-stage biotechnology company developing therapies and vaccines targeting cancers and infectious diseases. The company applies multiple immunotherapy and cell therapy approachesâincluding engineered cytokine fusion proteins, synthetic immunomodulators, and both natural killer and T-cell platformsâand has candidates in Phase II/III trials for solid and liquid tumors (for example, bladder, pancreatic and lung cancers) as well as antiviral programs for pathogens such as SARS-CoV-2 and HIV. It maintains research collaborations and licensing arrangements with U.S. government institutes and several biopharma partners and is headquartered in San Diego, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jan 16 | Jan 23 | IBRX | ImmunityBio, Inc. | ImmunityBio is a hot idea driven by accelerating commercial revenue growth (700% annual increase in 2025), regulatory approvals expanding markets, positive clinical data mid-January 2026, nearly doubled stock price in past month, despite ongoing financial risks. | Active | +0.0% |